Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Abramson Cancer Center at Penn Medicine
Age
30–90
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Men aged 30 to 90 years old with prostate adenocarcinoma who have already made their treatment selection of RARP, and only men with an AUA symptom score greater than 7 will be included. All subjects must be able to read and comprehend fully the informed consent.
You may not be if
Men with prostate neoplasms other than adenocarcinoma
Subjects receiving other treatments for prostate cancer will be excluded.
Any subject with a preexisting bladder disease will be excluded.
Subjects with acute urinary retention and/or deceased gastrointestinal motility.
Subjects who are unwilling or unable to complete the subject questionnaires
Subjects, who in the opinion of the investigator, would be non-compliant with the majority of the visits scheduled or study procedures.
Clareo Health | A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy
